Go Pro
→ American’s Biggest Threat Is Here (From Goldco Direct, LLC) (Ad)tc pixel Free DERM Stock Alerts

Journey Medical (DERM) Financials

Journey Medical logo
$7.11 -0.05 (-0.70%)
As of 03:49 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Journey Medical

Annual Income Statements for Journey Medical

This table shows Journey Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 5.28 -44 -30 -3.85 -15 -11
Consolidated Net Income / (Loss)		 5.28 -44 -30 -3.85 -15 -11
Net Income / (Loss) Continuing Operations		 5.28 -44 -30 -3.85 -15 -11
Total Pre-Tax Income 		7.15 -42 -30 -3.63 -15 -11
Total Operating Income		 7.85 -35 -28 -2.07 -14 -8.17
Total Gross Profit		 30 31 43 56 35 41
Total Revenue		 45 63 74 79 56 62
Operating Revenue		 45 63 74 79 56 62
Total Cost of Revenue		 15 32 31 23 21 21
Operating Cost of Revenue		 15 32 31 23 21 21
Total Operating Expenses		 22 66 70 58 49 49
Selling, General & Admin Expense		 22 40 59 44 40 44
Research & Development Expense		 0.00 17 11 7.54 9.86 0.48
Amortization Expense		 - - - 3.77 3.42 4.26
Other Operating Expenses / (Income)		 0.00 9.54 - 0.00 -4.55 0.00
Total Other Income / (Expense), net		 -0.70 -7.48 -2.05 -1.56 -0.93 -3.20
Interest Expense		 0.70 7.03 2.02 1.70 1.58 3.70
Interest & Investment Income		 - 0.00 0.06 0.32 0.76 0.59
Other Income / (Expense), net		 0.00 -0.45 -0.09 -0.18 -0.12 -0.09
Income Tax Expense		 1.87 1.63 0.06 0.22 0.06 0.06
Basic Earnings per Share		 $0.58 ($4.32) ($1.69) ($0.21) ($0.72) ($0.47)
Weighted Average Basic Shares Outstanding		 9.14M 10.19M 17.53M 18.23M 20.43M 24.50M
Diluted Earnings per Share		 $0.49 ($4.32) ($1.69) ($0.21) ($0.72) ($0.47)
Weighted Average Diluted Shares Outstanding		 10.84M 10.19M 17.83M 18.23M 20.43M 24.50M
Weighted Average Basic & Diluted Shares Outstanding		 - 17.32M 17.83M 19.93M 23.10M 27.33M

Quarterly Income Statements for Journey Medical

This table shows Journey Medical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 17 -2.14 -10 -3.36 -2.39 1.52 -4.07 -3.80 -2.32 -1.25 -2.23
Consolidated Net Income / (Loss)		 17 -2.14 -10 -3.36 -2.39 1.52 -4.07 -3.80 -2.32 -1.25 -2.23
Net Income / (Loss) Continuing Operations		 17 -2.14 -10 -3.36 -2.39 1.52 -4.07 -3.80 -2.32 -1.25 -2.23
Total Pre-Tax Income 		17 -2.02 -10 -3.36 -2.39 1.58 -4.07 -3.74 -2.32 -1.25 -2.23
Total Operating Income		 17 -2.10 -10 -2.93 -2.89 2.23 -3.32 -2.88 -1.53 -0.44 -1.49
Total Gross Profit		 28 13 7.03 9.13 10 11 8.35 10 12 11 9.74
Total Revenue		 35 15 13 15 15 14 13 15 18 16 16
Operating Revenue		 35 15 13 15 15 14 13 15 18 16 16
Total Cost of Revenue		 6.43 2.25 6.00 5.73 4.47 2.24 4.79 4.94 5.76 5.44 6.22
Operating Cost of Revenue		 6.43 2.25 6.00 5.73 4.47 2.24 4.79 4.94 5.76 5.44 6.22
Total Operating Expenses		 11 15 17 12 13 9.15 12 13 13 11 11
Selling, General & Admin Expense		 8.64 9.84 8.42 10 11 10 11 12 12 9.86 10
Research & Development Expense		 2.23 1.51 7.88 0.91 0.84 0.22 0.04 0.00 0.29 0.15 0.00
Amortization Expense		 - - 0.81 0.81 0.81 - 1.07 1.06 1.06 1.07 1.13
Total Other Income / (Expense), net		 -0.36 0.09 -0.35 -0.43 0.50 -0.65 -0.75 -0.86 -0.79 -0.80 -0.74
Interest Expense		 0.27 0.02 0.55 0.56 -0.37 0.83 0.89 0.94 0.94 0.93 0.89
Interest & Investment Income		 0.01 0.11 0.22 0.16 0.19 0.19 0.15 0.14 0.15 0.15 0.16
Other Income / (Expense), net		 -0.10 -0.00 -0.02 -0.03 -0.05 -0.01 -0.01 -0.06 -0.00 -0.02 -0.00
Basic Earnings per Share		 $0.91 ($0.09) ($0.53) ($0.17) ($0.12) $0.10 ($0.18) ($0.16) ($0.09) ($0.04) ($0.08)
Weighted Average Basic Shares Outstanding		 18.42M 18.23M 19.76M 19.99M 20.54M 20.43M 22.61M 23.29M 24.96M 24.50M 27.31M
Diluted Earnings per Share		 $0.80 $0.02 ($0.53) ($0.17) ($0.12) $0.10 ($0.18) ($0.16) ($0.09) ($0.04) ($0.08)
Weighted Average Diluted Shares Outstanding		 21.03M 18.23M 19.76M 19.99M 20.54M 20.43M 22.61M 23.29M 24.96M 24.50M 27.31M
Weighted Average Basic & Diluted Shares Outstanding		 18.51M 19.93M 20.01M 20.73M 20.89M 23.10M 23.30M 24.38M 27.14M 27.33M 27.53M

Annual Cash Flow Statements for Journey Medical

This table details how cash moves in and out of Journey Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 3.45 41 -17 -4.56 -7.13 3.79
Net Cash From Operating Activities		 5.13 -2.18 -14 5.24 -9.13 -12
Net Cash From Continuing Operating Activities		 5.13 -2.18 -14 5.24 -9.13 -12
Net Income / (Loss) Continuing Operations		 5.28 -44 -30 -3.85 -15 -11
Consolidated Net Income / (Loss)		 5.28 -44 -30 -3.85 -15 -11
Amortization Expense		 1.51 5.13 4.43 4.12 3.82 4.81
Non-Cash Adjustments To Reconcile Net Income		 0.90 22 5.16 6.32 5.73 5.92
Changes in Operating Assets and Liabilities, net		 -2.57 14 6.51 -1.35 -4.00 -12
Net Cash From Investing Activities		 -1.20 -10 -20 -5.00 -15 0.00
Net Cash From Continuing Investing Activities		 -1.20 -10 -20 -5.00 -15 0.00
Purchase of Property, Plant & Equipment		 - 0.00 -20 -5.00 -15 0.00
Net Cash From Financing Activities		 -0.49 53 16 -4.80 17 16
Net Cash From Continuing Financing Activities		 -0.49 53 16 -4.80 17 16
Repayment of Debt		 -0.50 -13 -8.08 -52 -1.30 -0.70
Issuance of Debt		 0.00 17 25 43 10 0.00
Issuance of Common Equity		 0.00 33 0.00 4.49 8.09 17
Other Financing Activities, net		 0.01 0.01 0.14 0.12 0.21 0.35
Cash Interest Paid		 - 0.00 0.99 1.13 2.01 3.24
Cash Income Taxes Paid		 0.11 0.16 0.17 0.18 0.13 0.05

Quarterly Cash Flow Statements for Journey Medical

This table details how cash moves in and out of Journey Medical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 7.77 2.69 -3.38 -0.15 -1.45 -2.16 0.77 -0.78 4.66 -0.86 3.13
Net Cash From Operating Activities		 19 -17 -5.02 -5.18 -1.16 2.23 -2.83 -0.94 -2.38 -6.28 2.91
Net Cash From Continuing Operating Activities		 19 -17 -5.02 -5.18 -1.16 2.23 -2.83 -0.94 -2.38 -6.28 2.91
Net Income / (Loss) Continuing Operations		 17 -2.14 -10 -3.36 -2.39 1.52 -4.07 -3.80 -2.32 -1.25 -2.23
Consolidated Net Income / (Loss)		 17 -2.14 -10 -3.36 -2.39 1.52 -4.07 -3.80 -2.32 -1.25 -2.23
Amortization Expense		 0.89 0.75 0.90 0.90 0.92 1.01 1.19 1.21 1.21 1.21 1.25
Non-Cash Adjustments To Reconcile Net Income		 1.12 -0.36 1.39 1.86 1.27 1.30 1.39 1.35 1.79 1.41 1.01
Changes in Operating Assets and Liabilities, net		 -0.06 -15 3.13 -4.58 -0.96 -1.60 -1.34 0.29 -3.06 -7.65 2.88
Net Cash From Investing Activities		 - - 0.00 - - -15 0.00 - - - 0.00
Net Cash From Continuing Investing Activities		 - - 0.00 - - -15 0.00 - - - 0.00
Net Cash From Financing Activities		 -11 19 1.64 5.03 -0.29 11 3.60 0.17 7.04 5.43 0.22
Net Cash From Continuing Financing Activities		 -11 19 1.64 5.03 -0.29 11 3.60 0.17 7.04 5.43 0.22
Repayment of Debt		 -11 -0.38 0.00 - -0.63 -0.68 -0.63 - -0.08 - 0.00
Issuance of Common Equity		 - 4.49 1.57 - 0.32 6.20 4.15 - 7.01 5.42 0.15
Other Financing Activities, net		 0.02 0.10 0.07 0.03 0.06 0.05 0.08 0.17 0.10 0.01 0.07
Cash Interest Paid		 0.12 - 0.27 0.49 0.59 0.67 0.81 0.78 0.81 0.83 0.81

Annual Balance Sheets for Journey Medical

This table presents Journey Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 52 97 105 77 80 95
Total Current Assets		 35 84 78 56 48 67
Cash & Equivalents		 8.25 49 32 27 20 24
Accounts Receivable		 24 23 28 15 10 30
Inventories, net		 1.40 9.86 14 10 14 9.62
Prepaid Expenses		 1.66 2.44 3.31 3.59 3.21 3.38
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 17 13 27 20 32 28
Intangible Assets		 15 13 27 20 32 28
Other Noncurrent Operating Assets		 0.18 0.24 0.28 0.11 0.20 0.11
Total Liabilities & Shareholders' Equity		 52 97 105 77 80 95
Total Liabilities		 42 55 88 56 60 63
Total Current Liabilities		 28 52 67 42 35 37
Short-Term Debt		 4.52 0.81 2.95 - - 0.00
Accounts Payable		 1.96 23 37 18 16 8.85
Accrued Expenses		 21 23 19 20 17 28
Current Deferred & Payable Income Tax Liabilities		 - 0.01 0.04 0.05 0.06 0.07
Other Current Liabilities		 0.09 4.61 2.74 3.29 1.24 0.56
Other Current Nonoperating Liabilities		 - 0.00 0.16 0.02 0.40 0.40
Total Noncurrent Liabilities		 14 3.63 21 15 25 25
Long-Term Debt		 13 0.00 20 15 25 25
Other Noncurrent Operating Liabilities		 0.10 3.63 1.52 0.01 0.12 0.02
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 10 42 17 20 20 32
Total Preferred & Common Equity		 10 42 17 20 20 32
Total Common Equity		 10 42 17 20 20 32
Common Stock		 5.17 81 85 93 107 130
Retained Earnings		 5.12 -39 -69 -72 -87 -98

Quarterly Balance Sheets for Journey Medical

This table presents Journey Medical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 66 67 65 64 85 81 85 92
Total Current Assets		 45 47 46 46 54 51 56 65
Cash & Equivalents		 25 24 24 22 21 20 25 27
Accounts Receivable		 7.99 9.80 10 11 18 16 18 25
Inventories, net		 11 11 9.69 12 12 13 12 9.29
Prepaid Expenses		 0.92 2.58 2.41 1.24 2.40 2.48 1.64 3.46
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 21 20 19 18 31 30 29 27
Intangible Assets		 21 19 19 18 31 30 29 26
Other Noncurrent Operating Assets		 0.13 0.09 0.06 0.04 0.18 0.16 0.13 0.09
Total Liabilities & Shareholders' Equity		 66 67 65 64 85 81 85 92
Total Liabilities		 49 54 54 53 63 62 59 61
Total Current Liabilities		 49 39 34 33 40 40 40 38
Short-Term Debt		 0.00 - - - 1.88 3.75 5.63 2.50
Accounts Payable		 28 15 15 15 14 13 12 8.20
Accrued Expenses		 16 20 16 16 23 23 21 26
Current Deferred & Payable Income Tax Liabilities		 0.13 0.04 0.00 0.00 0.06 0.07 0.07 0.07
Other Current Liabilities		 4.19 3.28 3.32 1.65 0.49 0.94 0.85 0.57
Other Current Nonoperating Liabilities		 0.00 0.24 0.25 0.33 0.38 0.42 0.42 0.39
Total Noncurrent Liabilities		 0.03 15 20 20 23 21 20 23
Long-Term Debt		 0.00 15 20 20 23 21 20 23
Other Noncurrent Operating Liabilities		 0.03 0.00 0.00 0.00 0.09 0.07 0.04 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 17 13 11 11 22 19 26 31
Total Preferred & Common Equity		 17 13 11 11 22 19 26 31
Total Common Equity		 17 13 11 11 22 19 26 31
Common Stock		 88 96 97 99 113 114 123 132
Retained Earnings		 -70 -83 -86 -89 -91 -95 -97 -101

Annual Metrics And Ratios for Journey Medical

This table displays calculated financial ratios and metrics derived from Journey Medical's official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 16,659,646.00 17,704,325.00 18,508,449.00 - 27,135,905.00
DEI Adjusted Shares Outstanding		 0.00 16,659,646.00 17,704,325.00 18,508,449.00 - 27,135,905.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -2.64 -1.67 -0.21 - -0.42
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 41.78% 16.69% 7.48% -29.11% 10.20%
EBITDA Growth		 0.00% -422.37% 23.24% 108.06% -638.94% 65.40%
EBIT Growth		 0.00% -549.98% 21.86% 91.83% -511.39% 40.10%
NOPAT Growth		 0.00% -521.08% 21.11% 92.47% -559.77% 40.25%
Net Income Growth		 0.00% -932.75% 32.65% 87.00% -280.79% 22.09%
EPS Growth		 0.00% -981.63% 60.88% 87.57% -242.86% 34.72%
Operating Cash Flow Growth		 0.00% -142.50% -520.54% 138.72% -274.18% -36.31%
Free Cash Flow Firm Growth		 0.00% 0.00% -2,025.90% 96.73% -2,376.07% 47.87%
Invested Capital Growth		 0.00% -131.25% 227.10% -4.52% 231.53% 33.50%
Revenue Q/Q Growth		 0.00% 0.00% -2.06% -0.89% -2.83% 4.14%
EBITDA Q/Q Growth		 0.00% 0.00% -10.49% 133.48% 30.87% -257.14%
EBIT Q/Q Growth		 0.00% 0.00% -3.86% 77.91% 23.88% -48.12%
NOPAT Q/Q Growth		 0.00% 0.00% -3.53% 79.20% 24.08% -48.72%
Net Income Q/Q Growth		 0.00% 0.00% 27.27% 68.81% 19.98% -31.95%
EPS Q/Q Growth		 0.00% 0.00% 42.91% 75.00% 10.00% -42.42%
Operating Cash Flow Q/Q Growth		 0.00% -135.88% -4.88% -70.77% 67.25% -216.40%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -109.40% 5.26% 35.24%
Invested Capital Q/Q Growth		 0.00% 0.00% -29.52% 202.44% 191.86% 26.06%
Profitability Metrics		 - - - - - -
Gross Margin		 67.23% 49.18% 58.23% 71.09% 62.81% 66.17%
EBITDA Margin		 21.03% -47.83% -31.46% 2.36% -17.93% -5.58%
Operating Margin		 17.63% -55.25% -37.35% -2.62% -24.36% -13.21%
EBIT Margin		 17.63% -55.96% -37.47% -2.85% -24.57% -13.36%
Profit (Net Income) Margin		 11.86% -69.68% -40.22% -4.87% -26.14% -18.48%
Tax Burden Percent		 73.86% 103.86% 100.21% 106.08% 100.42% 100.53%
Interest Burden Percent		 91.11% 119.90% 107.10% 160.99% 105.93% 137.63%
Effective Tax Rate		 26.14% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 29.10% -356.47% -2,283.57% -18.76% -58.73% -19.56%
ROIC Less NNEP Spread (ROIC-NNEP)		 23.75% -255.13% -2,247.41% 3.21% 71.70% -193.59%
Return on Net Nonoperating Assets (RNNOA)		 22.23% 188.35% 2,183.18% -1.88% -13.87% -24.47%
Return on Equity (ROE)		 51.33% -168.12% -100.39% -20.64% -72.60% -44.03%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -422.10% -14.13% -166.04% -48.25%
Operating Return on Assets (OROA)		 15.13% -47.36% -27.27% -2.48% -17.56% -9.45%
Return on Assets (ROA)		 10.18% -58.98% -29.27% -4.23% -18.68% -13.08%
Return on Common Equity (ROCE)		 51.33% -168.12% -100.39% -20.64% -72.60% -44.03%
Return on Equity Simple (ROE_SIMPLE)		 51.33% -104.64% -174.47% -18.93% -73.11% 0.00%
Net Operating Profit after Tax (NOPAT)		 5.80 -24 -19 -1.45 -9.57 -5.72
NOPAT Margin		 13.02% -38.67% -26.15% -1.83% -17.06% -9.25%
Net Nonoperating Expense Percent (NNEP)		 5.35% -101.34% -36.16% -21.97% -130.44% 174.02%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -4.15% -21.30% -10.01%
Cost of Revenue to Revenue		 32.77% 50.82% 41.77% 28.91% 37.19% 33.83%
SG&A Expenses to Revenue		 49.60% 63.09% 80.72% 55.46% 71.62% 71.73%
R&D to Revenue		 0.00% 26.23% 14.85% 9.52% 17.56% 0.78%
Operating Expenses to Revenue		 49.60% 104.43% 95.58% 73.71% 87.17% 79.39%
Earnings before Interest and Taxes (EBIT)		 7.85 -35 -28 -2.26 -14 -8.26
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 9.37 -30 -23 1.87 -10 -3.45
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 3.42 2.13 2.00 5.24 4.07 6.57
Price to Tangible Book Value (P/TBV)		 0.00 3.04 0.00 1,692.20 0.00 49.26
Price to Revenue (P/Rev)		 0.79 1.42 0.46 1.35 1.46 3.38
Price to Earnings (P/E)		 6.66 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 15.01% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.25 0.00 3.13 12.41 3.44 6.29
Enterprise Value to Revenue (EV/Rev)		 1.01 0.66 0.34 1.18 1.54 3.40
Enterprise Value to EBITDA (EV/EBITDA)		 4.79 0.00 0.00 50.24 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 5.71 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 7.73 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 8.74 0.00 0.00 17.90 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 23.85 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 1.74 0.02 1.34 0.72 1.24 0.79
Long-Term Debt to Equity		 1.30 0.00 1.17 0.72 1.24 0.79
Financial Leverage		 0.94 -0.74 -0.97 -0.59 -0.19 0.13
Leverage Ratio		 5.04 2.85 3.43 4.88 3.89 3.37
Compound Leverage Factor		 4.60 3.42 3.67 7.85 4.12 4.63
Debt to Total Capital		 63.47% 1.89% 57.28% 41.81% 55.35% 44.25%
Short-Term Debt to Total Capital		 16.05% 1.89% 7.42% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 47.41% 0.00% 49.87% 41.81% 55.35% 44.25%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 36.53% 98.11% 42.72% 58.19% 44.65% 55.75%
Debt to EBITDA		 1.91 -0.03 -0.98 7.83 -2.47 -7.33
Net Debt to EBITDA		 1.03 1.60 0.40 -6.87 -0.45 -0.34
Long-Term Debt to EBITDA		 1.43 0.00 -0.86 7.83 -2.47 -7.33
Debt to NOPAT		 3.08 -0.03 -1.18 -10.08 -2.60 -4.42
Net Debt to NOPAT		 1.66 1.98 0.48 8.83 -0.48 -0.21
Long-Term Debt to NOPAT		 2.30 0.00 -1.03 -10.08 -2.60 -4.42
Altman Z-Score		 2.17 0.27 -0.72 0.98 -0.38 1.28
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 1.26 1.64 1.16 1.35 1.37 1.79
Quick Ratio		 1.15 1.40 0.90 1.02 0.87 1.44
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 1.73 -33 -1.09 -27 -14
Operating Cash Flow to CapEx		 0.00% 0.00% -67.67% 104.80% -60.85% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.25 -16.54 -0.64 -17.18 -3.82
Operating Cash Flow to Interest Expense		 7.35 -0.31 -6.70 3.09 -5.79 -3.36
Operating Cash Flow Less CapEx to Interest Expense		 7.35 -0.31 -16.61 0.14 -15.32 -3.36
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.86 0.85 0.73 0.87 0.71 0.71
Accounts Receivable Turnover		 1.86 2.68 2.87 3.65 4.41 3.09
Inventory Turnover		 10.39 5.70 2.56 1.88 1.69 1.74
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 7.46 2.53 1.03 0.84 1.22 1.68
Days Sales Outstanding (DSO)		 196.13 135.98 127.13 100.10 82.75 118.05
Days Inventory Outstanding (DIO)		 35.11 64.08 142.45 194.23 215.35 209.81
Days Payable Outstanding (DPO)		 48.92 144.53 355.94 436.21 298.93 217.19
Cash Conversion Cycle (CCC)		 182.32 55.53 -86.36 -141.88 -0.83 110.67
Capital & Investment Metrics		 - - - - - -
Invested Capital		 20 -6.23 7.91 7.56 25 33
Invested Capital Turnover		 2.23 9.22 87.34 10.24 3.44 2.12
Increase / (Decrease) in Invested Capital		 0.00 -26 14 -0.36 17 8.39
Enterprise Value (EV)		 45 41 25 94 86 210
Market Capitalization		 35 90 34 107 82 209
Book Value per Share		 $1.13 $2.52 $0.96 $1.10 $0.96 $1.17
Tangible Book Value per Share		 ($0.52) $1.77 ($0.58) $0.00 ($0.56) $0.16
Total Capital		 28 43 40 35 45 57
Total Debt		 18 0.81 23 15 25 25
Total Long-Term Debt		 13 0.00 20 15 25 25
Net Debt		 9.63 -48 -9.23 -13 4.57 1.19
Capital Expenditures (CapEx)		 0.00 0.00 20 5.00 15 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 3.46 -15 -18 -13 -7.30 5.34
Debt-free Net Working Capital (DFNWC)		 12 34 14 15 13 29
Net Working Capital (NWC)		 7.18 33 11 15 13 29
Net Nonoperating Expense (NNE)		 0.52 20 10 2.40 5.10 5.71
Net Nonoperating Obligations (NNO)		 9.63 -48 -9.07 -13 4.98 1.59
Total Depreciation and Amortization (D&A)		 1.52 5.13 4.43 4.12 3.73 4.81
Debt-free, Cash-free Net Working Capital to Revenue		 7.76% -24.38% -24.72% -16.23% -13.01% 8.63%
Debt-free Net Working Capital to Revenue		 26.28% 53.36% 18.73% 18.42% 23.17% 47.58%
Net Working Capital to Revenue		 16.13% 52.08% 14.72% 18.42% 23.17% 47.58%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($4.32) ($1.69) ($0.21) ($0.72) ($0.47)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 10.19M 17.53M 18.23M 20.43M 24.50M
Adjusted Diluted Earnings per Share		 $0.00 ($4.32) ($1.69) ($0.21) ($0.72) ($0.47)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 10.19M 17.53M 19.93M 20.43M 24.50M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 17.32M 17.83M 19.93M 23.10M 27.33M
Normalized Net Operating Profit after Tax (NOPAT)		 5.80 -24 -19 0.75 -9.57 -5.72
Normalized NOPAT Margin		 13.02% -38.67% -26.15% 0.95% -17.06% -9.25%
Pre Tax Income Margin		 16.06% -67.10% -40.13% -4.59% -26.03% -18.38%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 11.25 -5.02 -13.67 -1.33 -8.76 -2.23
NOPAT to Interest Expense		 8.31 -3.47 -9.54 -0.85 -6.08 -1.55
EBIT Less CapEx to Interest Expense		 11.25 -5.02 -23.58 -4.27 -18.28 -2.23
NOPAT Less CapEx to Interest Expense		 8.31 -3.47 -19.45 -3.80 -15.60 -1.55
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -3.52% -1.25% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Journey Medical

This table displays calculated financial ratios and metrics derived from Journey Medical's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 18,475,115.00 18,508,449.00 20,012,896.00 20,012,896.00 20,727,237.00 - 23,104,437.00 23,295,769.00 24,378,186.00 27,135,905.00 27,330,696.00
DEI Adjusted Shares Outstanding		 18,475,115.00 18,508,449.00 20,012,896.00 20,012,896.00 20,727,237.00 - 23,104,437.00 23,295,769.00 24,378,186.00 27,135,905.00 27,330,696.00
DEI Earnings Per Adjusted Shares Outstanding		 0.91 -0.12 -0.52 -0.17 -0.12 - -0.18 -0.16 -0.10 -0.05 -0.08
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 114.32% -4.44% 6.69% -13.49% -57.65% -10.73% 0.84% 1.04% 20.52% 18.05% 21.48%
EBITDA Growth		 313.27% 84.61% -8.39% 67.45% -111.20% 338.40% 76.73% 16.00% 84.02% -77.58% 88.34%
EBIT Growth		 280.20% 79.07% -5.24% 61.50% -117.18% 205.51% 67.06% 0.74% 47.98% -120.79% 55.12%
NOPAT Growth		 358.08% 78.95% -5.53% 61.75% -111.81% 251.68% 67.06% 1.74% 47.17% -113.88% 55.11%
Net Income Growth		 266.56% 79.86% -3.02% 59.81% -114.24% 170.98% 60.99% -12.94% 3.14% -181.99% 45.25%
EPS Growth		 240.35% 103.28% 7.02% 63.04% -115.00% 400.00% 66.04% 5.88% 25.00% -140.00% 55.56%
Operating Cash Flow Growth		 357.44% -330.66% -425.00% -230.41% -106.17% 113.47% 43.57% 81.80% -105.96% -382.43% 202.72%
Free Cash Flow Firm Growth		 448.84% 94.73% 63.08% -224.89% -150.30% -1,268.68% -1,172.71% -16.67% -5.73% 42.98% 81.15%
Invested Capital Growth		 -165.68% -4.52% -70.96% 206.22% 216.37% 231.53% 576.41% 231.63% 209.08% 33.50% 13.72%
Revenue Q/Q Growth		 101.14% -55.83% -14.60% 14.01% -1.52% -6.90% -3.53% 14.23% 17.47% -8.80% -0.73%
EBITDA Q/Q Growth		 385.55% -107.51% -580.43% 77.68% 1.70% 259.72% -164.60% 19.45% 81.30% 330.34% -133.60%
EBIT Q/Q Growth		 323.05% -112.28% -380.10% 70.73% 0.47% 175.45% -249.91% 11.83% 47.84% 69.84% -223.59%
NOPAT Q/Q Growth		 420.10% -108.59% -379.56% 70.99% 1.13% 210.28% -204.15% 13.48% 46.84% 71.03% -236.79%
Net Income Q/Q Growth		 300.75% -112.76% -387.26% 67.81% 28.89% 163.64% -367.78% 6.80% 39.01% 46.13% -78.83%
EPS Q/Q Growth		 273.91% -97.50% -2,750.00% 67.92% 29.41% 183.33% -280.00% 11.11% 43.75% 55.56% -100.00%
Operating Cash Flow Q/Q Growth		 372.34% -188.12% 69.62% -3.13% 77.65% 292.31% -227.28% 66.74% -152.97% -163.70% 146.29%
Free Cash Flow Firm Q/Q Growth		 172.58% -103.12% 303.53% -821.94% -9.78% 15.15% -59.52% 21.48% 0.52% 54.24% 47.27%
Invested Capital Q/Q Growth		 -6.12% 202.44% -49.45% 93.30% 16.26% 191.86% 3.13% -5.23% 8.35% 26.06% -12.15%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 81.39% 85.27% 53.94% 61.45% 69.44% 83.58% 63.54% 67.09% 67.36% 66.17% 61.04%
EBITDA Margin		 52.23% -8.87% -70.71% -13.84% -13.82% 23.70% -16.32% -11.51% -1.83% 4.63% -1.57%
Operating Margin		 49.93% -13.79% -77.44% -19.70% -19.78% 16.40% -25.30% -19.16% -8.67% -2.76% -9.35%
EBIT Margin		 49.64% -13.80% -77.60% -19.92% -20.13% 16.31% -25.35% -19.57% -8.69% -2.87% -9.37%
Profit (Net Income) Margin		 48.61% -14.05% -80.14% -22.63% -16.34% 11.17% -31.00% -25.29% -13.13% -7.76% -13.97%
Tax Burden Percent		 99.44% 106.25% 100.00% 100.00% 100.00% 96.14% 100.00% 101.61% 100.00% 100.00% 100.00%
Interest Burden Percent		 98.48% 95.77% 103.27% 113.59% 81.15% 71.20% 122.28% 127.20% 151.11% 269.91% 149.16%
Effective Tax Rate		 0.56% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 2,058.86% -98.83% -511.06% -4,960.31% -1,325.61% 56.48% -67.18% -47.48% -20.54% -4.08% -15.33%
ROIC Less NNEP Spread (ROIC-NNEP)		 2,060.67% -92.70% -316.47% -4,936.17% -1,322.92% 74.73% 4.96% -317.20% 124.44% -32.63% -98.97%
Return on Net Nonoperating Assets (RNNOA)		 -1,878.39% 54.29% 53.76% 4,747.46% 1,266.50% -14.45% -0.70% -13.73% -5.80% -4.12% -5.36%
Return on Equity (ROE)		 180.47% -44.54% -457.30% -212.86% -59.11% 42.03% -67.88% -61.21% -26.34% -8.20% -20.69%
Cash Return on Invested Capital (CROIC)		 0.00% -14.13% 88.52% -165.38% -332.88% -166.04% -181.11% -137.47% -124.13% -48.25% -28.91%
Operating Return on Assets (OROA)		 45.56% -12.01% -76.44% -22.93% -17.90% 11.66% -18.82% -15.08% -6.92% -2.03% -6.87%
Return on Assets (ROA)		 44.62% -12.22% -78.94% -26.05% -14.52% 7.98% -23.01% -19.49% -10.45% -5.49% -10.24%
Return on Common Equity (ROCE)		 180.47% -44.54% -457.30% -212.86% -59.11% 42.03% -67.88% -61.21% -26.34% -8.20% -20.69%
Return on Equity Simple (ROE_SIMPLE)		 -71.09% 0.00% -32.11% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 17 -1.47 -7.06 -2.05 -2.03 2.23 -2.33 -2.01 -1.07 -0.31 -1.04
NOPAT Margin		 49.65% -9.65% -54.21% -13.79% -13.85% 16.40% -17.71% -13.41% -6.07% -1.93% -6.54%
Net Nonoperating Expense Percent (NNEP)		 -1.81% -6.13% -194.59% -24.15% -2.69% -18.24% -72.14% 269.71% -144.99% 28.55% 83.64%
Return On Investment Capital (ROIC_SIMPLE)		 - -4.21% -25.56% -6.60% -6.60% 4.97% -5.00% -4.54% -2.10% -0.54% -1.86%
Cost of Revenue to Revenue		 18.61% 14.73% 46.06% 38.55% 30.56% 16.42% 36.46% 32.91% 32.64% 33.83% 38.96%
SG&A Expenses to Revenue		 25.00% 64.50% 64.62% 69.53% 77.90% 73.86% 80.44% 79.17% 68.37% 61.34% 63.34%
R&D to Revenue		 6.45% 9.86% 60.51% 6.15% 5.76% 1.60% 0.30% 0.00% 1.63% 0.96% 0.00%
Operating Expenses to Revenue		 31.46% 99.06% 131.37% 81.15% 89.22% 67.17% 88.84% 86.25% 76.03% 68.92% 70.39%
Earnings before Interest and Taxes (EBIT)		 17 -2.11 -10 -2.96 -2.95 2.22 -3.33 -2.94 -1.53 -0.46 -1.50
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 18 -1.35 -9.21 -2.06 -2.02 3.23 -2.14 -1.73 -0.32 0.74 -0.25
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.91 5.24 5.66 9.99 10.72 4.07 6.33 8.69 6.70 6.57 4.16
Price to Tangible Book Value (P/TBV)		 0.00 1,692.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00 49.26 29.45
Price to Revenue (P/Rev)		 0.63 1.35 0.92 1.45 2.03 1.46 2.42 2.97 2.92 3.38 1.98
Price to Earnings (P/E)		 0.00 0.00 0.00 133.89 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.75% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 12.41 16.75 14.73 13.33 3.44 5.43 7.03 6.55 6.29 4.30
Enterprise Value to Revenue (EV/Rev)		 0.32 1.18 0.80 1.40 1.98 1.54 2.49 3.05 2.93 3.40 1.95
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 50.24 55.44 20.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 55.24 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 51.18 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 1.44 17.90 54.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 2.23 0.00 8.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.72 1.13 1.75 1.81 1.24 1.16 1.30 0.97 0.79 0.82
Long-Term Debt to Equity		 0.00 0.72 1.13 1.75 1.81 1.24 1.07 1.11 0.75 0.79 0.74
Financial Leverage		 -0.91 -0.59 -0.17 -0.96 -0.96 -0.19 -0.14 0.04 -0.05 0.13 0.05
Leverage Ratio		 4.00 4.88 7.95 11.94 4.59 3.89 4.39 4.79 4.05 3.37 3.37
Compound Leverage Factor		 3.94 4.67 8.21 13.56 3.73 2.77 5.37 6.10 6.12 9.09 5.03
Debt to Total Capital		 0.00% 41.81% 53.14% 63.62% 64.42% 55.35% 53.70% 56.61% 49.28% 44.25% 45.14%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4.03% 8.45% 11.02% 0.00% 4.45%
Long-Term Debt to Total Capital		 0.00% 41.81% 53.14% 63.62% 64.42% 55.35% 49.67% 48.16% 38.26% 44.25% 40.70%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 58.19% 46.86% 36.39% 35.58% 44.65% 46.30% 43.39% 50.72% 55.75% 54.86%
Debt to EBITDA		 0.00 7.83 12.72 3.65 -1.35 -2.47 -8.61 -9.43 -26.04 -7.33 -16.31
Net Debt to EBITDA		 0.00 -6.87 -8.12 -0.77 0.18 -0.45 -1.35 -1.81 -0.22 -0.34 1.19
Long-Term Debt to EBITDA		 0.00 7.83 12.72 3.65 -1.35 -2.47 -7.96 -8.02 -20.22 -7.33 -14.70
Debt to NOPAT		 0.00 -10.08 -8.06 9.30 -1.57 -2.60 -5.16 -5.23 -6.54 -4.42 -5.72
Net Debt to NOPAT		 0.00 8.83 5.15 -1.96 0.21 -0.48 -0.81 -1.00 -0.05 -0.21 0.42
Long-Term Debt to NOPAT		 0.00 -10.08 -8.06 9.30 -1.57 -2.60 -4.78 -4.45 -5.08 -4.42 -5.15
Altman Z-Score		 1.14 0.98 -0.07 0.68 0.38 0.28 0.52 0.72 1.03 1.55 0.74
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.92 1.35 1.21 1.36 1.38 1.37 1.34 1.27 1.42 1.79 1.72
Quick Ratio		 0.67 1.02 0.87 1.01 0.99 0.87 0.97 0.89 1.08 1.44 1.38
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 36 -1.11 2.27 -16 -18 -15 -24 -19 -19 -8.70 -4.59
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 14.83% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 133.40 -46.45 4.14 -29.10 0.00 -18.36 -27.32 -20.40 -20.29 -9.32 -5.14
Operating Cash Flow to Interest Expense		 69.95 -688.33 -9.16 -9.19 0.00 2.68 -3.18 -1.01 -2.54 -6.74 3.26
Operating Cash Flow Less CapEx to Interest Expense		 69.95 -688.33 -9.16 -9.19 0.00 -15.37 -3.18 -1.01 -2.54 -6.74 3.26
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.92 0.87 0.99 1.15 0.89 0.71 0.74 0.77 0.80 0.71 0.73
Accounts Receivable Turnover		 4.37 3.65 4.28 5.71 6.19 4.41 4.04 4.32 4.15 3.09 3.01
Inventory Turnover		 2.16 1.88 1.88 1.87 1.62 1.69 1.70 1.68 1.71 1.74 2.05
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.92 0.84 0.76 0.88 0.85 1.22 1.32 1.38 1.50 1.68 1.98
Days Sales Outstanding (DSO)		 83.43 100.10 85.36 63.91 58.95 82.75 90.28 84.49 88.04 118.05 121.38
Days Inventory Outstanding (DIO)		 168.93 194.23 193.98 195.44 225.67 215.35 214.13 217.88 213.66 209.81 177.90
Days Payable Outstanding (DPO)		 398.06 436.21 482.72 414.77 430.36 298.93 276.04 264.47 243.44 217.19 184.57
Cash Conversion Cycle (CCC)		 -145.70 -141.88 -203.39 -155.42 -145.74 -0.83 28.38 37.90 58.26 110.67 114.70
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -7.38 7.56 3.82 7.38 8.58 25 26 24 27 33 29
Invested Capital Turnover		 41.47 10.24 9.43 359.63 95.73 3.44 3.79 3.54 3.38 2.12 2.34
Increase / (Decrease) in Invested Capital		 -19 -0.36 -9.33 14 16 17 22 17 18 8.39 3.54
Enterprise Value (EV)		 26 94 64 109 114 86 140 172 174 210 126
Market Capitalization		 51 107 73 113 117 82 136 167 174 209 128
Book Value per Share		 $0.94 $1.10 $0.65 $0.56 $0.53 $0.96 $0.93 $0.83 $1.06 $1.17 $1.13
Tangible Book Value per Share		 ($0.20) $0.00 ($0.33) ($0.37) ($0.33) ($0.56) ($0.40) ($0.45) ($0.11) $0.16 $0.16
Total Capital		 17 35 28 31 31 45 47 44 51 57 56
Total Debt		 0.00 15 15 20 20 25 25 25 25 25 25
Total Long-Term Debt		 0.00 15 15 20 20 25 23 21 20 25 23
Net Debt		 -25 -13 -9.37 -4.16 -2.68 4.57 3.91 4.82 0.21 1.19 -1.85
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 15 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -29 -13 -16 -12 -9.63 -7.30 -5.43 -5.76 -2.65 5.34 2.42
Debt-free Net Working Capital (DFNWC)		 -3.82 15 8.08 12 13 13 16 15 22 29 30
Net Working Capital (NWC)		 -3.82 15 8.08 12 13 13 14 11 17 29 27
Net Nonoperating Expense (NNE)		 0.36 0.67 3.38 1.31 0.36 0.71 1.75 1.78 1.24 0.94 1.19
Net Nonoperating Obligations (NNO)		 -25 -13 -9.13 -3.91 -2.34 4.98 4.29 5.24 0.63 1.59 -1.46
Total Depreciation and Amortization (D&A)		 0.89 0.75 0.90 0.90 0.92 1.01 1.19 1.21 1.21 1.21 1.25
Debt-free, Cash-free Net Working Capital to Revenue		 -35.77% -16.23% -19.98% -14.92% -16.67% -13.01% -9.66% -10.21% -4.46% 8.63% 3.74%
Debt-free Net Working Capital to Revenue		 -4.79% 18.42% 10.10% 15.86% 22.21% 23.17% 27.81% 25.78% 37.54% 47.58% 45.82%
Net Working Capital to Revenue		 -4.79% 18.42% 10.10% 15.86% 22.21% 23.17% 24.47% 19.13% 28.07% 47.58% 41.96%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.91 ($0.09) ($0.53) ($0.17) ($0.12) $0.10 ($0.18) ($0.16) ($0.09) ($0.04) ($0.08)
Adjusted Weighted Average Basic Shares Outstanding		 18.42M 18.23M 19.76M 19.99M 20.54M 20.43M 22.61M 23.29M 24.96M 24.50M 27.31M
Adjusted Diluted Earnings per Share		 $0.80 $0.02 ($0.53) ($0.17) ($0.12) $0.10 ($0.18) ($0.16) ($0.09) ($0.04) ($0.08)
Adjusted Weighted Average Diluted Shares Outstanding		 21.03M 18.23M 19.76M 19.99M 20.54M 20.43M 22.61M 23.29M 24.96M 24.50M 27.31M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 18.51M 19.93M 20.01M 20.73M 20.89M 23.10M 23.30M 24.38M 27.14M 27.33M 27.53M
Normalized Net Operating Profit after Tax (NOPAT)		 17 -1.47 -7.06 -2.05 -2.03 1.56 -2.33 -2.01 -1.07 -0.31 -1.04
Normalized NOPAT Margin		 49.65% -9.65% -54.21% -13.79% -13.85% 11.48% -17.71% -13.41% -6.07% -1.93% -6.54%
Pre Tax Income Margin		 48.88% -13.22% -80.14% -22.63% -16.34% 11.62% -31.00% -24.89% -13.13% -7.76% -13.97%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 63.97 -87.75 -18.45 -5.26 0.00 2.67 -3.74 -3.13 -1.64 -0.50 -1.68
NOPAT to Interest Expense		 63.99 -61.37 -12.89 -3.64 0.00 2.69 -2.61 -2.15 -1.14 -0.33 -1.17
EBIT Less CapEx to Interest Expense		 63.97 -87.75 -18.45 -5.26 0.00 -15.38 -3.74 -3.13 -1.64 -0.50 -1.68
NOPAT Less CapEx to Interest Expense		 63.99 -61.37 -12.89 -3.64 0.00 -15.36 -2.61 -2.15 -1.14 -0.33 -1.17
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Journey Medical (NASDAQ: DERM) showed a mixed start to 2026, with revenue growth versus the prior quarter, but continued operating losses and a still-heavy debt load. The company remains cash-generative at the operating level in Q1 2026, but its profitability trend is still inconsistent and highly sensitive to operating expenses and interest costs.

  • Q1 2026 revenue increased sequentially to $15.96 million from $16.08 million in Q4 2025, and was up from $13.14 million in Q1 2025, showing a better top-line trend over the past year.
  • Gross profit remained solid at $9.74 million in Q1 2026, with gross margin near 61%, indicating the core product economics are still healthy.
  • Operating cash flow was positive in Q1 2026 at $2.91 million, compared with negative operating cash flow in several prior quarters, helped by favorable working-capital changes.
  • Cash and equivalents increased to $27.22 million at March 31, 2026, up from $24.95 million at the end of Q3 2025.
  • Book equity improved to $30.83 million, versus $25.90 million in Q3 2025 and $21.54 million in Q1 2025, reflecting a stronger balance sheet cushion.
  • Revenue remains fairly stable quarter to quarter, but growth has not yet translated into consistent net profitability.
  • Amortization remains meaningful at about $1.25 million in Q1 2026, which helps support cash flow but also highlights the ongoing cost structure tied to prior asset purchases.
  • Share count has risen over time, with weighted average basic shares at 27.3 million in Q1 2026 versus 22.6 million in Q1 2025, which can dilute future per-share results.
  • DERM reported a net loss of $2.23 million in Q1 2026, though that was an improvement from the $3.80 million loss in Q2 2025 and $4.07 million loss in Q1 2025.
  • Interest expense remains a major burden: Q1 2026 interest expense was $892,000, and cash interest paid was $806,000, limiting bottom-line progress.
  • Debt is still significant at $25.37 million total debt in Q1 2026, including $2.5 million short-term debt and $22.87 million long-term debt.
  • Operating expenses are still high relative to revenue, especially SG&A, which was $10.11 million in Q1 2026 and nearly erased gross profit on its own.
  • Working-capital swings can materially affect cash flow, as seen in prior quarters when operating cash flow turned sharply negative despite relatively steady sales.

Bottom line: Journey Medical is showing some encouraging signs, especially with positive operating cash flow in Q1 2026 and a stronger cash balance. But the company is still not consistently profitable, and its debt service plus SG&A burden remain the biggest hurdles for investors to watch.

07/20/26 03:49 PM ETAI Generated. May Contain Errors.

Journey Medical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Journey Medical's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Journey Medical's net income appears to be on a downward trend, with a most recent value of -$11.43 million in 2025, falling from $5.28 million in 2020. The previous period was -$14.67 million in 2024. View Journey Medical's forecast to see where analysts expect Journey Medical to go next.

Journey Medical's total operating income in 2025 was -$8.17 million, based on the following breakdown:
  • Total Gross Profit: $40.93 million
  • Total Operating Expenses: $49.11 million

Over the last 5 years, Journey Medical's total revenue changed from $44.53 million in 2020 to $61.86 million in 2025, a change of 38.9%.

Journey Medical's total liabilities were at $62.74 million at the end of 2025, a 4.3% increase from 2024, and a 50.8% increase since 2020.

In the past 5 years, Journey Medical's cash and equivalents has ranged from $8.25 million in 2020 to $49.08 million in 2021, and is currently $24.09 million as of their latest financial filing in 2025.

Over the last 5 years, Journey Medical's book value per share changed from 1.13 in 2020 to 1.17 in 2025, a change of 4.2%.


Related Companies

Financial statements for NASDAQ:DERM last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Buy this stock tomorrow
Marc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...
Chaikin Analytics | Sponsoredtc pixel
Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...
Paradigm Press | Sponsoredtc pixel
SMX: From Under-the-Radar to Must-Watch!
SMX (Security Matters) PLC is building Digital Material Passport technology that embeds molecular-level marker...
Smallcaps Daily | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
American’s Biggest Threat Is Here
This feels like one of those ''where were you when Kennedy was shot'' moments. It felt like a moment in time, ...
Goldco Direct, LLC | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
27 insiders just called an emergency meeting
A staggering $122 million traded on Polymarket and another $64 million on Kalshi on whether America would win ...
Crypto 101 Media | Sponsoredtc pixel